基于临床试验标准评价维立西呱在真实世界心力衰竭治疗中适用性的研究进展

Research advances of dosing vericiguat in the treatment of heart failure in real world based upon clinical trial criteria

基于临床试验结果,维立西呱先后在美国、日本、欧盟和中国获批上市,并获得相关指南推荐用于治疗射血分数降低(射血分数<45%)的心力衰竭患者。该研究首先介绍了维立西呱药学特性及临床试验结果,随后综述了近期基于临床试验标准探讨维立西呱在真实世界心力衰竭治疗中适用性的研究进展,以期为临床心力衰竭治疗提供参考。

Vericiguat has been approved in the United States,Japan,European Union and China.It is indicated for heart fail⁃ure(HF)with reduced ejection fraction(<45%).Here pharmaceutical characteristics and clinical trial results of vericiguat were summarized.This review focused upon the latest applications of vericiguat for HF based upon clinical trial criteria in real world.It provided references for proper managements of HR.